These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37653631)

  • 1. PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme.
    da Silva ALL; de Araújo TPG; de Albuquerque Ferreira SC; Leite AB; da Silva JKS; Albuquerque LWN; de Lima ARV; Barros HCS; Silva LR; da Silva-Júnior EF; de Araújo-Júnior JX; Neto VM; de Queiroz AC; Alexandre-Moreira MS
    Curr Protein Pept Sci; 2024; 25(1):12-26. PubMed ID: 37653631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
    Aguila B; Morris AB; Spina R; Bar E; Schraner J; Vinkler R; Sohn JW; Welford SM
    Cancer Lett; 2019 Oct; 462():33-42. PubMed ID: 31377205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
    Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
    J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
    Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
    Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K Pathway Inhibition with NVP-BEZ235 Hinders Glycolytic Metabolism in Glioblastoma Multiforme Cells.
    Udawant S; Litif C; Lopez A; Gunn B; Schuenzel E; Keniry M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).
    Khabibov M; Garifullin A; Boumber Y; Khaddour K; Fernandez M; Khamitov F; Khalikova L; Kuznetsova N; Kit O; Kharin L
    Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35445737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3Kinase signaling in glioblastoma.
    Lino MM; Merlo A
    J Neurooncol; 2011 Jul; 103(3):417-27. PubMed ID: 21063898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.
    Mu Q; Wang L; Yu F; Gao H; Lei T; Li P; Liu P; Zheng X; Hu X; Chen Y; Jiang Z; Sayari AJ; Shen J; Huang H
    Cancer Biol Ther; 2015; 16(4):623-33. PubMed ID: 25719943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the AKT pathway in glioblastoma.
    McDowell KA; Riggins GJ; Gallia GL
    Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
    Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
    PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions.
    Hashemi M; Etemad S; Rezaei S; Ziaolhagh S; Rajabi R; Rahmanian P; Abdi S; Koohpar ZK; Rafiei R; Raei B; Ahmadi F; Salimimoghadam S; Aref AR; Zandieh MA; Entezari M; Taheriazam A; Hushmandi K
    Biomed Pharmacother; 2023 Feb; 158():114204. PubMed ID: 36916430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
    Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
    Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor.
    Li S; Guo W; Gao Y; Liu Y
    Tumour Biol; 2015 Apr; 36(4):2607-12. PubMed ID: 25431263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
    Feng SW; Wu ZS; Chiu YL; Huang SM
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
    Tanaka K; Babic I; Nathanson D; Akhavan D; Guo D; Gini B; Dang J; Zhu S; Yang H; De Jesus J; Amzajerdi AN; Zhang Y; Dibble CC; Dan H; Rinkenbaugh A; Yong WH; Vinters HV; Gera JF; Cavenee WK; Cloughesy TF; Manning BD; Baldwin AS; Mischel PS
    Cancer Discov; 2011 Nov; 1(6):524-38. PubMed ID: 22145100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human glioblastoma multiforme cells by 10,11-dehydrocurvularin through the MMP-2 and PI3K/AKT signaling pathways.
    Yan H; Fu Z; Lin P; Gu Y; Cao J; Li Y
    Eur J Pharmacol; 2022 Dec; 936():175348. PubMed ID: 36306925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.
    Xu Y; Stamenkovic I; Yu Q
    Cancer Res; 2010 Mar; 70(6):2455-64. PubMed ID: 20197461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
    Mao H; Lebrun DG; Yang J; Zhu VF; Li M
    Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.